Skip to content
Verovaccines logo — VEROVACCiNES creates affordable animal vaccines through inno...

Verovaccines

VEROVACCiNES creates affordable animal vaccines through innovative technology, with the ability to combine multiple antigens in one vaccine.

Founded 2017 2-10 employees Series B Total: $3.10M Biotechnology, Health Care +1

General Information

Company Name Verovaccines
Founded Year 2017
Employees 2-10
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Verovaccines. To contact Verovaccines, visit verovaccines.org.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Verovaccines compare?

A PDF of Verovaccines and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Verovaccines soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Verovaccines

Verovaccines is a biotechnology startup dedicated to creating affordable animal vaccines through innovative technology, with the ability to combine multiple antigens in one vaccine. The company's proprietary technology offers an effective and economical means of developing vaccines, reducing immunization effort, and minimizing antibiotic use. With a focus on improving animal health, Verovaccines' latest breakthrough allows for the integration of multiple antigens into a single vaccine without increasing production costs. This advancement paves the way for the creation of vaccines that can target multiple pathogens or provide immunity to various strains of the same pathogen. Established in 2017, the startup has developed five vaccine programs, with four of them having already achieved proof of concept. The pipeline includes several candidates with the potential to become blockbusters, offering comprehensive solutions for the poultry, swine, and ruminant industries. Verovaccines' most recent Series B investment on 14 October 2021 was secured from the German Federal Ministry of Education and Research, demonstrating confidence in the company's potential within the biotechnology, health care, and pharmaceutical sectors.

Business keywords: Animal Vaccines, Innovative Technology, Subunit Marker Vaccines, Multivalent Vaccines, Cost-Effective Manufacturing, Combination Vaccine, Thermostability, IP, Veterinary Pharmaceuticals, Collaborations

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B Undisclosed 1
German Federal Ministry of Education and Research
14 Oct 2021
Seed Round Undisclosed 3
German Federal Ministry of Education and Research, Business Angels Switzerland (BAS) +1
03 Dec 2019
Grant €3.10M 1
German Federal Ministry of Education and Research
17 Apr 2018

Verovaccines Alternatives & Competitors

View All Alternatives
Verovaccines vs

Game-changing animal disease prevention with orally-delivered, RT stable, cost effective vaccines fo...

Series A
21 employees
Biotechnology, Health Care
Verovaccines vs
FeedVax
FeedVax United States

Oral vaccines for Aquaculture

Venture round
15 employees
Agriculture, Biotechnology
Verovaccines vs

A vaccine plattform company

11 employees
Biotechnology, Health Care

FAQ About Verovaccines

VEROVACCiNES creates affordable animal vaccines through innovative technology, with the ability to combine multiple antigens in one vaccine.
Verovaccines was founded in 2017.
Verovaccines operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Animal Vaccines, Innovative Technology, Subunit Marker Vaccines and Multivalent Vaccines.
Verovaccines has approximately 2-10 employees.
Verovaccines has completed 3 funding rounds, raising a total of $3.10M. The latest funding stage is Series B.
Top alternatives and competitors to Verovaccines include Mazen Animal Health - Oral Vaccines, FeedVax, Abera Bioscience AB, Tréidlia Biovet, Innovac Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Verovaccines and Mazen Animal Health - Oral Vaccines are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Verovaccines, https://bouncewatch.com/company/verovaccines, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout